Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $10.8 million.

  • SAB Biotherapeutics' Total Current Liabilities rose 2242.63% to $10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 2242.63%. This contributed to the annual value of $8.0 million for FY2024, which is 2620.58% down from last year.
  • SAB Biotherapeutics' Total Current Liabilities amounted to $10.8 million in Q3 2025, which was up 2242.63% from $10.7 million recorded in Q2 2025.
  • SAB Biotherapeutics' Total Current Liabilities' 5-year high stood at $26.5 million during Q4 2021, with a 5-year trough of $80000.0 in Q1 2021.
  • Its 5-year average for Total Current Liabilities is $10.7 million, with a median of $10.7 million in 2025.
  • Per our database at Business Quant, SAB Biotherapeutics' Total Current Liabilities skyrocketed by 2398829.75% in 2022 and then crashed by 4613.88% in 2023.
  • Quarter analysis of 5 years shows SAB Biotherapeutics' Total Current Liabilities stood at $26.5 million in 2021, then plummeted by 43.33% to $15.0 million in 2022, then dropped by 27.88% to $10.8 million in 2023, then fell by 26.21% to $8.0 million in 2024, then soared by 35.26% to $10.8 million in 2025.
  • Its Total Current Liabilities stands at $10.8 million for Q3 2025, versus $10.7 million for Q2 2025 and $9.7 million for Q1 2025.